Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules
- 86% achieved the primary endpoint, at least 50% nodule-volume reduction
- Median nodule-volume reduction reached 72%, with most reduction by one month
- Quality-of-life impact improved 78%, while 82% reported complete resolution of neck pressure or fullness
- No serious adverse events reported, strengthening the device’s safety and commercialization case
Item EX-99.1 · Exhibit EX-99.1
- Interim six-month PRECISE-BTN results support clinical efficacy: 86% of 43 evaluated patients achieved at least 50% nodule reduction
- Median nodule volume reduction reached 72%, with improvement beginning by one month after a single treatment
- Quality-of-life impact improved 78%, while neck pressure or fullness resolved in 82% of affected patients
- No serious adverse events reported, supporting nsPFA’s potential safety advantage over thermal or surgical alternatives
- Full 100-patient six-month results and 12-month follow-up remain key catalysts for validation and regulatory progress
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.